Royce & Associates LP lowered its stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 45.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 534,953 shares of the company’s stock after selling 444,711 shares during the period. Royce & Associates LP owned 0.52% of Oric Pharmaceuticals worth $7,206,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of ORIC. BlackRock Inc. acquired a new position in Oric Pharmaceuticals during the 2nd quarter worth $73,904,000. Siren L.L.C. boosted its position in Oric Pharmaceuticals by 197.6% in the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock valued at $37,987,000 after buying an additional 1,990,617 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Oric Pharmaceuticals by 19.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock valued at $18,637,000 after buying an additional 244,060 shares during the last quarter. Bank of America Corp DE boosted its position in Oric Pharmaceuticals by 105.5% in the 1st quarter. Bank of America Corp DE now owns 1,043,159 shares of the company’s stock valued at $13,217,000 after buying an additional 535,649 shares during the last quarter. Finally, Algert Global LLC increased its stake in shares of Oric Pharmaceuticals by 791.3% in the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock valued at $13,162,000 after buying an additional 1,078,943 shares during the period. Institutional investors and hedge funds own 95.05% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ORIC. Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. JPMorgan Chase & Co. upped their price target on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Leerink Partners started coverage on Oric Pharmaceuticals in a report on Monday, October 5th. They issued an “outperform” rating and a $26.00 price target on the stock. HC Wainwright raised their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, Citigroup lifted their price objective on Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Oric Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.17.
Insider Buying and Selling
In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 14,000 shares of the stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total value of $189,420.00. Following the transaction, the chief financial officer owned 69,828 shares of the company’s stock, valued at approximately $944,772.84. This represents a 16.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock valued at $1,432,952 in the last ninety days. Corporate insiders own 5.70% of the company’s stock.
Oric Pharmaceuticals Stock Performance
ORIC opened at $7.65 on Thursday. The company has a fifty day moving average price of $11.26 and a two-hundred day moving average price of $10.96. Oric Pharmaceuticals, Inc. has a 52 week low of $7.23 and a 52 week high of $14.68. The firm has a market capitalization of $792.95 million, a PE ratio of -5.24 and a beta of 1.23.
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05). Equities analysts forecast that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current year.
More Oric Pharmaceuticals News
Here’s some of the latest news about ORIC:
- Positive Sentiment: Citigroup raised its price target to $17 from $16 and reiterated a “buy” rating. BTIG also reaffirmed “buy” with a $26 target. Citigroup rating BTIG rating
- Positive Sentiment: Wells Fargo maintained its “overweight” rating, although it lowered its target to $23 from $25. Wells Fargo rating
- Neutral Sentiment: A separate report put analysts’ consensus price target at $21.33, indicating that coverage remains broadly optimistic, though price targets are not guarantees. Consensus price target report
About Oric Pharmaceuticals
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Further Reading
- Five stocks we like better than Oric Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
